Foster Jonathan P. 4

What Happened

• Jonathan P. Foster, CFO of Moleculin Biotech (MBRX), had restricted stock units (RSUs) convert into 283 shares of common stock across two vesting events (109 shares on 2026-06-20 and 174 shares on 2026-06-22). Of those, 72 shares were withheld to cover tax liabilities (31 shares at $2.88 = $89 and 41 shares at $3.12 = $128). Net shares delivered to Foster were 211 shares.
• The filing shows the RSU conversions reported as derivative conversions (transaction code M) and the withholding as tax-related dispositions (transaction code F). The derivative conversion lines report $0 proceeds because they reflect conversion/settlement of RSUs, not a cash sale.

Key Details

• Transaction dates and prices: 2026-06-20 (109 RSUs vested; 31 shares withheld at $2.88 = $89), 2026-06-22 (174 RSUs vested; 41 shares withheld at $3.12 = $128).
• Net shares received: 283 vested − 72 withheld = 211 shares added to Foster’s account.
• Holdings note: the filing indicates holdings include 100,003 shares underlying Series E warrants (see footnote).
• Relevant footnotes: F1 (RSUs convert one-for-one), F2 (shares withheld for tax withholding), F3/F4 (original RSU grants in 2022 and 2023 vesting over four years).
• Timeliness: Filing date 2026-06-24 for events on 6/20 and 6/22 — appears timely.

Context

• These transactions are routine RSU vesting and tax-withholding events, not open-market purchases or sales. The conversion of RSUs to common stock is recorded as a derivative exercise; the withholding of shares to satisfy taxes (a common cashless withholding) reduces the number of shares delivered to the insider but does not indicate an outright sale to the market.
• For retail investors, such vesting is informational about insider compensation and ownership changes but should not be taken alone as a signal of management sentiment.